Continuous ambulatory peritoneal dialysis (CAPO)
is reported to ameliorate anemia in many chronic renal failure patients, at least during the first year of dialysis. The elevation of circulating levels of erythropoietin (EPa), combined with a more efficient removal of inhibitors of its action by CAPO, has been proposed as an explanation of this phenomenon (1, 2) .
However, measurements of serum EPa levels in CAPO patients have given variable results. Thus Wideroe et al. (3) reported an improvement of the plasma EPa stimulating activity in CAPD patients. By contrast, Lamperi et al. could not find any significant difference in serum EPa levels between CAPD and hemodialysis (4) . Moreover, the "removal" of inhibitors of EPa action by CAPD procedure, remains an attractive but unproven hypothesis.
Even though the hematocrit generally improves with CAPO, some patients remain severely anemic (5) . Giving iron (4) or small doses of nandrolone (6) has helped some of the patients, but others continue to require blood transfusions to maintain their hematocrit around 20% (5, 6) . Such treatment, however, is only transiently effective. It increases the risk of exposure to hepatitis and iron overload. It also renders the patient transfusion dependent (7).
Since EPa has been offered as a biologically active substance from recombinant sources (8), several studies have shown its effectiveness for the specific treatment of anemia in hemodialysis patients (9-12). Here, we review, its use in peritoneal dialysis patients.
Pharmacokinetic studies
Experimental studies in the rabbit (13) have shown that r-Hu EPa is well absorbed from the peritoneal cavity when there is no dialysate in it. In a CAPDlike regimen however, the peritoneal absorption of the drug is significantly reduced.
What is known about the pharmacokinetics of r-Hu EPa in man derives from the study of a single dose of the drug given intravenously (i.v.), intraperitoneally (i.p.), or subcutaneously (s.c.) in peritoneal dialysis patients (14, 15) .
After l.v. administration the volume of distribution and the half-life of r-Hu EPa were similar to those reported in hemodialysis patients (16, 17) . This is expected because the high molecular weight of ':he drug (30.400 daltons) results in a peritoneal clears nce of about 0.12 ml/min (15) .
Intraperitoneal administration of r-Hu EPa produces a low peak concentration of the drug in the serum which is not influenced significantly when the dwell time ranges between 4 and 12 hours (15) . It is notable that following drainage of the peritoneal cavity serum EPa levels continue to rise even if the peritoneum is refilled by an EPa free dialysate (14) . This observation leads to the speculation that the peritoneal lymphatic system may play an important role in the pooling of the drug into the peritoneum (14) . However there is yet no specific study concerning the route of absorption of the r-Hu EPa molecule from the peritoneal cavity.
When r-Hu EPa is administered subcutaneously it continuous to be absorbed for 48 to 72 hours after the injection (15) . Comparing the data on the bioavailability of r-Hu EPa following s.c. or i.p. administration makes it apparent that the i.p, dose has to be 5 to 10 times higher than the s.c. in order to achieve the same blood levels (14) .
Clinical experience
Some clinical experience with s.c. use of r-Hu EPa in CAPD patients for a few weeks has been reported. In a recent study (18) five transfusion dependent young patients treated with continuous cycling peritoneal dialysis (CCPD), were given 150 U/kg of body weight of r-Hu EPa s.c. three times a week. Three weeks later the hematocrit had risen in all patients and the dose was reduced in order to keep the hematocrit at 32 to 38%. Three patients had an exacerbation of previously existing hypertension and required adjustment of their antihypertensive therapy. In another pilot study, a s.c. dosage of 50 U/kg of body weight every 48 hours in CAPO patients caused a clear rise in hemoglobin (19) .
CONCLUSION
Since CAPO is a form of home dialysis the i.v, administration of r-Hu EPO is clearly inconvenient. Nor does the i.p. route seem to be a reasonable means of treatment for a CAPO patient, because of the limited absorption and consequent waste of an expensive medication.
With intermittent peritoneal dialysis (I PO), r-Hu EPO could be administered at the end of the session, because, theoretically and according to the findings of Bargman et al. (13) , the peritoneal absorption improves when the peritoneal cavity is empty. By the same token CCPO patients could receive r-Hu EPO by the i.p, route because they use a low day time volume of dialysate. However, these theoretical possibilities would need clinical confirmation by carefully designed prospective studies.
The s.c. route remains the most attractive way of administration of r-Hu EPO in peritoneal dialysis patients. This route has led to a 50% reduction of the i.v. dose for the same clinical effect in hemodialysis patients (20) . Still to be worked out, however, are the exact pharmaco-kinetics following repeated s.c. doses of r-Hu EPO, since a progressive increase in the serum levels of the drug is quite possible. Long term results of the s.c. administration of r-Hu EPO are eagerly awaited. 
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